Icapamespib

Icapamespib (PU-HZ151; PU-AD) is a selective, orally active inhibitor of Epichaperomes assembled by HSP90 with slow dissociation kinetics. Icapamespib can cross the blood-brain barrier (BBB) ??and induce epichaperome disassembly by non-covalently binding to HSP90, restoring the normal protein-protein interaction network. Icapamespib can specifically disrupt disease-related abnormal protein interaction networks, reduce neurotoxic protein aggregation and tumor cell survival signals. Icapamespib can be used in the research of neurodegenerative diseases such as Alzheimer's disease, as well as cancers such as glioblastoma and metastatic breast cancer[1][2][3].

Product Specifications

CAS Number

[1000999-96-1]

Product Name Alternative

PU-HZ151

UNSPSC

12352005

Target

HSP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/icapamespib.html

Purity

99.60

Solubility

DMSO : ≥ 100 mg/mL

Smiles

IC1=C(SC2=NC3=C(N)N=CN=C3N2CCNCC(C)(C)C)C=C4OCOC4=C1

Molecular Formula

C19H23IN6O2S

Molecular Weight

526.39

References & Citations

[1]Bolaender A, et al. Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. Nat Commun. 2021;12 (1) :4669. Published 2021 Aug 3.|[2]Pasala C, et al. Epichaperomes: redefining chaperone biology and therapeutic strategies in complex diseases. RSC Chem Biol. 2025 Mar 19;6 (5) :678-698.|[3]Bay S, et al. Synthesis and Characterization of Click Chemical Probes for Single-Cell Resolution Detection of Epichaperomes in Neurodegenerative Disorders. Biomedicines. 2024 Jun 4;12 (6) :1252.